VIVORYON overview

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) dose Statistically significant improvement in...

Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the full year 2023 and...

Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced changes among the Non-Executive members of its Board of Directors. Professor Morten Asser Karsdal, MSc, PhD, mMBA...

Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer ’ s Disease VIVIAD Phase 2b study did not meet its primary and key secondary endpoints Varoglutamstat was generally well tolerated with low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs in the clinical setting VIVIAD is a comprehensive, diligently designed and high-quality study; baseline demographics in the study were highly representative of early AD...

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Halle (Saale) / Munich, Germany, January 8, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that members of its management team including CEO Frank Weber, MD, CBO Michael Schaeffer, PhD, and CS & IRO Anne...

Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress VIVIAD and VIVA-MIND studies both advancing as planned at 600mg twice daily following positive DSMB decisions; VIVIAD safety update with cut-off as of November 20, 2023, confirms low level of discontinuations On track to report VIVIAD final topline Phase 2b data during end of Q1/2024 Commenced preparations for VIVALONG, an open-label extension study Unveiling focused growth strategy...

Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Halle (Saale) / Munich, Germany, November 28, 2023 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its third quarter financial results for the period...